We proposed a potential clinical trial of a total of 6 months of anti-HER2 therapy for patients with HER2-positive EBC who receive neoadjuvant systemic chemotherapy and anti-HER2 therapy and achieve a pCR, with no residual invasive breast cancer found in the breast and/or axilla at the time of surgery. This evidence concerns the gene ERBB2 and invasive breast carcinoma.